Optimising regulatory T cell depletion in combination with chemotherapy for enhanced anti-tumour immunity [ 2009 - 2012 ]

Also known as: Chemotherapy and regulatory T cells

Research Grant

[Cite as]

Researchers: Prof Anna Nowak (Principal investigator) ,  Dr Robbert Van Der Most Prof Bruce Robinson Prof Michael Millward Prof Richard Lake

Brief description The drug cyclophosphamide helps the immune system attack cancer by decreasing the number of immune cells that suppress an immune response to cancer ('Regulatory T cells'). This project combines standard chemotherapy with the drug cyclophosphamide in people with mesothelioma and lung cancer. The aim of the project is to find the dose of cyclophosphamide that maximally decreases Regulatory T cells in each patient, and determine the effect of this on anti-tumour immunity and response to treatment.

Funding Amount $AUD 264,816.34

Funding Scheme NHMRC Project Grants

Notes Standard Project Grant

Click to explore relationships graph
Viewed: [[ro.stat.viewed]]